Plain-English translation of NCT07551635 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new drug called for people with extensive-stage small-cell lung cancer that has come back or worsened after prior chemotherapy. The medication targets cancer cells that have a specific marker called POU2F3 expression. This is an early-stage trial, so the medication has not yet been approved by the FDA.
Small-cell lung cancer is aggressive and often comes back after standard chemotherapy. Researchers believe this medication may work for patients whose cancer has this specific POU2F3 marker, offering a new treatment option when other therapies have stopped working.
You likely qualify if…
You likely don't qualify if…
You would visit the study site for a baseline appointment, then receive the medication once daily in 21-day cycles for as long as it is helping and you tolerate it well. During each cycle, you'll have blood tests, imaging scans (CT, MRI, or PET), heart function tests, and physical exams to monitor how you're responding. After you stop taking the medication, you'll return for a follow-up visit 30 days later, and then annually for up to 5 years.
AI-generated summary from trial data · Nov 17, 2026 · Not medical advice
United States